456 related articles for article (PubMed ID: 15470265)
21. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
22. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
[TBL] [Abstract][Full Text] [Related]
23. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.
Boukpessi T; Gaucher C; Léger T; Salmon B; Le Faouder J; Willig C; Rowe PS; Garabédian M; Meilhac O; Chaussain C
Am J Pathol; 2010 Aug; 177(2):803-12. PubMed ID: 20581062
[TBL] [Abstract][Full Text] [Related]
24. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
25. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
26. [Rickets].
Yasuda T
Clin Calcium; 2009 Jan; 19(1):109-16. PubMed ID: 19122271
[TBL] [Abstract][Full Text] [Related]
27. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
28. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
29. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
Saito T; Nishii Y; Yasuda T; Ito N; Suzuki H; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2009 Oct; 161(4):647-51. PubMed ID: 19581284
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel loss-of-function PHEX mutation, Ala720Ser, in a sporadic case of adult-onset hypophosphatemic osteomalacia.
Goljanek-Whysall K; Tridimas A; McCormick R; Russell NJ; Sloman M; Sorani A; Fraser WD; Hannan FM
Bone; 2018 Jan; 106():30-34. PubMed ID: 28982589
[TBL] [Abstract][Full Text] [Related]
31. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets.
Capelli S; Donghi V; Maruca K; Vezzoli G; Corbetta S; Brandi ML; Mora S; Weber G
Bone; 2015 Oct; 79():143-9. PubMed ID: 26051471
[TBL] [Abstract][Full Text] [Related]
32. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice.
Miao D; Bai X; Panda DK; Karaplis AC; Goltzman D; McKee MD
Bone; 2004 Apr; 34(4):638-47. PubMed ID: 15050894
[TBL] [Abstract][Full Text] [Related]
33. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
34. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
35. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
Kinoshita Y; Saito T; Shimizu Y; Hori M; Taguchi M; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2012 Aug; 167(2):165-72. PubMed ID: 22577109
[TBL] [Abstract][Full Text] [Related]
37. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
Karaplis AC; Bai X; Falet JP; Macica CM
Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
[TBL] [Abstract][Full Text] [Related]
38. FGF23 is processed by proprotein convertases but not by PHEX.
Benet-Pagès A; Lorenz-Depiereux B; Zischka H; White KE; Econs MJ; Strom TM
Bone; 2004 Aug; 35(2):455-62. PubMed ID: 15268897
[TBL] [Abstract][Full Text] [Related]
39. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
40. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets.
Ruppe MD; Brosnan PG; Au KS; Tran PX; Dominguez BW; Northrup H
Clin Endocrinol (Oxf); 2011 Mar; 74(3):312-8. PubMed ID: 21050253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
